Mechanisms Linking Inflammation to Insulin Resistance.
Chen L, Chen R, Wang H, Liang F, Liang F. · 2015
Read Mechanisms Linking Inflammation to Insulin Resistance. by Chen L, Chen R, Wang H, Liang F, Liang F. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4468292.txt.
Introduction
Li Chen, Rui Chen, Hua Wang, and Fengxia Liang reviewed how inflammation dulls the body's response to insulin, in the International Journal of Endocrinology in 2015. Obesity is now worldwide, and its long-lasting, low-grade inflammation is a main reason tissues stop answering insulin well. That resistance drives type 2 diabetes and metabolic syndrome.
Overfeeding fills fat cells with lipid, and fat tissue then releases inflammatory messengers and switches on signaling pathways that jam insulin's own signals in muscle, liver, and fat. Messengers and pathways influence each other, so both must be weighed together, the authors argue. They gather recent experimental work on each factor, from immune proteins to stress pathways inside cells. They also judge the promise of anti-inflammatory treatments. Such treatments could restore insulin action at its source, rather than only lower blood sugar.
Catalog record
| CREATOR | Chen L, Chen R, Wang H, Liang F, Liang F. |
|---|---|
| YEAR | 2015 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 46 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Mechanisms Linking Inflammation to Insulin Resistance By Li Chen, Rui Chen, Hua Wang, Fengxia Liang Published in: International Journal of Endocrinology DOI: 10.1155/2015/508409 ABSTRACT Abstract Obesity is now widespread around the world. Obesity-associated chronic low-grade inflammation is responsible for the decrease of insulin sensitivity, which makes obesity a major risk factor for insulin resistance and related diseases such as type 2 diabetes mellitus and metabolic syndromes. The state of low-grade inflammation is caused by overnutrition which leads to lipid accumulation in adipocytes. Obesity might increase the expression of some inflammatory cytokines and activate several signaling pathways, both of which are involved in the pathogenesis of insulin resistance by interfering with insulin signaling and action. It has been suggested that specific factors and signaling pathways are often correlated with each other; therefore, both of the fluctuation of cytokines and the status of relevant signaling pathways should be considered during studies analyzing inflammation-related insulin resistance. In this paper, we discuss how these factors and signaling pathways contribute to insulin resistance and the therapeutic promise targeting inflammation in insulin resistance based on the latest experimental studies. 1. INTRODUCTION Insulin resistance (IR) is a complicated condition in which three primary metabolic tissues that are sensitive to insulin, skeletal muscle, liver, and white adipose tissue (WAT) become less sensitive to insulin and its downstream metabolic actions under normal serum glucose concentrations [1]. IR is closely associated with obesity, hypertension, hyperglycaemia, polycystic ovary syndrome, and metabolic syndrome (see glossary) [2, 3]. As the key component of metabolic syndrome, IR is also closely associated with nonalcoholic fatty liver disease (NAFLD) [4]. The antilipolytic effect of insulin is decreased in insulin-resistant conditions, which may promote hepatic triglyceride synthesis. Another feature of insulin resistance is an increasing release of free fatty acid. As we know, FFA could be taken up by organs and accumulated as ectopic fat, such as hepatic and cardiac lipids [5]. And hepatic lipids including triglyceride deposition are involved in the pathogenesis and development of NAFLD. Several factors are implicated in the pathology of obesity-related NAFLD, including complex interactions between glucose and lipid metabolism, genetic predisposition, environmental conditions, and modulation of the intestinal microbiota [6]. IR encompasses a wide spectrum of disorders, such as defective insulin receptor signal transduction and mitochondrial function [7, 8], microvascular dysfunction [9, 10], and inflammation [11–13]. Obesity, characterized as a state of chronic low-grade inflammation caused by overnutrition, is a major cause of decreased insulin sensitivity, which makes obesity a major risk factor for IR [14–16]. Obesity, also manifested as excess adiposity, is a main cause of NAFLD [17]. NAFLD is recognized as a typical feature of metabolic syndrome and manifested as a series of hepatic injuries including steatosis, nonalcoholic steatohepatitis (NASH), and even hepatocellular carcinoma [18]. Obesity causes lipid accumulation in adipocytes, which activates c-Jun N-terminal kinase (JNK) and nuclear factor-kappa B (NF-κB) signaling pathways and might subsequently increase the production of proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) [11, 19]. In most cases, adipose tissue (AT) is an important site of obesity-induced IR, and it can also affect the liver and muscle by releasing cytokines, including adipokines such as TNF-α [11, 18]. AT consists of several cell types. Among these, adipocytes and immune cells, such as macrophages and dendritic cells (DCs), have attracted significant attention as contributors that link inflammation to IR. This review will focus on the relationship between inflammation and IR, and we analyze the mechanisms relating to how inflammatory cytokines, signaling pathways, and some other factors link inflammation to IR. 2. CYTOKINES THAT LINK INFLAMMATION TO IR 2.1. TNF-α Studies of TNF-α in the 1990s first analyzed the relationship between inflammation and IR [20]. TNF-α is an adipose tissue-derived proinflammatory cytokine that causes insulin resistance by enhancing adipocyte lipolysis and increasing the serine/threonine phosphorylation of IRS-1 (insulin receptor substrate-1) [11, 21]. Several signaling pathways, including the IKKβ/NF-κB pathway, are involved in the pathogenesis of IR (see Figure 1) [22, 23]. It was reported that TNF-α can increase glucose uptake in both visceral and subcutaneous adipocytes by activating the adenosine monophosphate activated protein kinase (AMPK) pathway, whereas it triggers insulin resistance in visceral adipocytes by activating JNK1/2. Because of the depot-specific effects of TNF-α on glucose uptake, approaches to treat IR by modulating TNF-α signaling are ongoing [24]. However, studies of therapies such as the TNF-α superfamily member sTWEAK (soluble tumour necrosis factor-like weak inducer of apoptosis), which aims to block TNF signaling to treat IR, have demonstrated that TNF-α plays a role in IR [25]. Interestingly, the plasma levels of TNF-α are higher in males than in females, as well as in obese individuals compared with lean ones. This suggests that obese males are more likely to suffer from IR and related diseases such as cardiovascular disease [26]. [Figure: Influence of the inflammatory cytokines on the status of insulin resistance. TNF-α causes insulin resistance by enhancing adipocyte lipolysis stimulating JNK and IKKβ/NF-κB pathway which may increase serine/threonine phosphorylation of IRS1. IL-6 induces IR by reducing the expression of GLUT4 and IRS-1 by activating the JAK-STAT signaling pathway and increasing SOCS3 expression, and IL-6 can also lead to IR in skeletal muscle by inducing TLR-4 gene expression through activation of STAT3; besides, TLR4 is suggested to be major upstream molecules in the activation of NF-κB. Besides, IL-6 is also found to induce IR by impairing the synthesis of glycogen through downregulating the expression of miR-200s and upregulating that of FOG-2.] 2.2. IL-1β Interleukin-1β (IL-1β) is a proinflammatory cytokine whose secretion is regulated by inflammasome activity. IL-1β contributes to IR by impairing insulin signaling in peripheral tissues and macrophages, which leads to the reduced insulin sensitivity of β-cells and possible impaired insulin secretion [27, 28]. The levels of IL-1β in various cells such as endothelial cells and monocytes are increased during hyperglycemia [29]. IL-1β also plays a vital role in initiating and maintaining inflammation-induced organ dysfunction in type 2 diabetes mellitus (T2DM) [30]. IL-1β might increase systemic inflammation and inhibit insulin action in the major insulin-target cells, such as macrophages [31]. 2.3. IL-6 IL-6 is secreted by multiple tissues, particularly adipose tissue, and is recognized as an inflammatory mediator that causes IR by reducing the expression of glucose transporter-4 (GLUT-4) and insulin receptor substrate-1 (IRS-1). These effects are exerted by the activation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway (see Box 1) and increased the expression of suppressor of cytokine signaling 3 (SOCS3) [32, 33] (see Figure 1). Therefore, hybrid training can ameliorate insulin resistance by suppressing serum IL-6 in skeletal muscle [34]. IL-6 also induces IR by blocking the phosphoinositide 3-kinase (PI3K) pathway and impairing glycogen synthesis by downregulating the expression of microRNA-200s (miR-200s) and upregulating that of friend of GATA 2 (FOG-2) [35, 36]. It was suggested that IR in human skeletal muscle is related to IL-6 stimulation, which induces toll-like receptor-4 (TLR-4) gene expression by activating STAT3 [37] (see Figure 1). 2.4. Leptin Leptin is a protein that is derived primarily from white adipose tissue (WAT) [38]. It suppresses appetite and increases energy expenditure by repressing anabolic neuronal circuits and activating catabolic neuronal circuits. In addition, leptin levels are affected by nutriture [39]. Leptin-mediated appetite and